Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of ($0.46), $0.17 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $196.83 million versus the consensus estimate of $200.09 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.